§ 06 · the inbox
Reach the editors
For citation corrections, source suggestions, or notes on the regulatory record. Not for medical advice and not for product inquiries.
What we are happy to hear about
We welcome notes on three things. First, citation corrections — if we have a DOI, a PMID, a date, or a dose value wrong, please tell us and we will check and revise. Second, new primary sources — if a new peer-reviewed trial, review, or regulatory document on sermorelin or the broader GHRH-analog literature has appeared, we want to know. Third, regulatory updates — the Section 503A bulks-list status of sermorelin can move with FDA rulemaking, and we maintain this notebook as an evidence binder rather than a static page; updates from readers who follow PCAC closely are valuable.
What we cannot help with
We cannot answer clinical questions. We are not clinicians, we do not have access to your medical history, and we do not make individual dosing or treatment recommendations of any kind. We also cannot help with product inquiries — we do not sell anything, we are not affiliated with any compounding pharmacy, telehealth practice, or vendor, and we cannot connect you to any of those services. Questions of either kind belong with a licensed clinician or a state-licensed Section 503A pharmacy, not with this publisher.
How to write to us
The contact form below routes to the editorial inbox. Please include in your note: the page on this site you are writing about, the specific claim or citation in question, and (for corrections) the source you believe supports the correction. We read everything; we cannot guarantee a reply, but corrections and source suggestions are prioritised. This form is not a medical-advice channel and is not a vendor inquiry channel — both will be respectfully declined.